Patent · US Active

Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer

US11931430B2 · kind B2 · utility

2Cited by

225References

15Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Matthias Eder · Freiburg (Elbe), DE
Klaus Kopka · Dossenheim, DE
Martin SCHÄFER · Neckarsteinach, DE
Ulrike BAUDER-WÜST · Schriesheim, DE
Michael Eisenhut · Heidelberg, DE
Walter Mier · Bensheim, DE
Martina Benesova · Neckarsteinach, DE

Key dates

Filing date	Dec 3, 2020
Grant date	Mar 19, 2024
Priority date	—
Expiry date	Dec 17, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D295/145
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.